Literature DB >> 23868299

Pheochromocytoma in an 8-year-old patient with multiple endocrine neoplasia type 2A: implications for screening.

Kathryn J Rowland1, Rebecca D Chernock, Jeffrey F Moley.   

Abstract

Childhood pheochromocytoma in the setting of multiple endocrine neoplasia type 2 (MEN2) remains rare and has not been reported under the age of 12. We present an 8-year-old female with known MEN 2A, C634Y RET mutation, diagnosed with a 6 cm pheochromocytoma requiring laparoscopic adrenalectomy. Given this patient's age at diagnosis, screening guidelines should recommend annual screening beginning at age 8 for patients with MEN 2B or MEN 2A codons 630 or 634 RET mutations.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  adrenalectomy; multiple endocrine neoplasia type 2; pheochromocytoma; screening

Mesh：

Substances：

Year:  2013        PMID： 23868299      PMCID： PMC3983847          DOI： 10.1002/jso.23378

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  16 in total

1.  A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan.

Authors:  M Iihara; T Yamashita; T Okamoto; M Kanbe; K Yamazaki; S Egawa; K Yamaguchi; T Obara
Journal:  Jpn J Clin Oncol       Date:  1997-06       Impact factor: 3.019

2.  Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma.

Authors:  F J Pomares; R Cañas; J M Rodriguez; A M Hernandez; P Parrilla; F J Tebar
Journal:  Clin Endocrinol (Oxf)       Date:  1998-02       Impact factor: 3.478

Review 3.  Multiple endocrine neoplasia type 2.

Authors:  Nelson Wohllk; Heiko Schweizer; Zoran Erlic; Kurt Werner Schmid; Martin K Walz; Friedhelm Raue; Hartmut P H Neumann
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

4.  Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2.

Authors:  Andreas Machens; Michael Brauckhoff; Hans-Jürgen Holzhausen; Phuong Nguyen Thanh; Hendrik Lehnert; Henning Dralle
Journal:  J Clin Endocrinol Metab       Date:  2005-04-12       Impact factor: 5.958

5.  Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group.

Authors:  E Modigliani; H M Vasen; K Raue; H Dralle; A Frilling; R G Gheri; M L Brandi; E Limbert; B Niederle; L Forgas
Journal:  J Intern Med       Date:  1995-10       Impact factor: 8.989

Review 6.  Sporadic and familial medullary thyroid carcinoma: state of the art.

Authors:  Tricia A Moo-Young; Amber L Traugott; Jeffrey F Moley
Journal:  Surg Clin North Am       Date:  2009-10       Impact factor: 2.741

7.  The natural course of multiple endocrine neoplasia type IIb. A study of 18 cases.

Authors:  H F Vasen; M van der Feltz; F Raue; A N Kruseman; H P Koppeschaar; G Pieters; F J Seif; W F Blum; C J Lips
Journal:  Arch Intern Med       Date:  1992-06

8.  Pheochromocytoma in MEN 2A syndrome. Study of 54 patients.

Authors:  Jose M Rodriguez; Maria Balsalobre; Jose L Ponce; Antonio Ríos; Nuria M Torregrosa; Javier Tebar; Pascual Parrilla
Journal:  World J Surg       Date:  2008-11       Impact factor: 3.352

9.  Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B.

Authors:  M A Skinner; M K DeBenedetti; J F Moley; J A Norton; S A Wells
Journal:  J Pediatr Surg       Date:  1996-01       Impact factor: 2.545

Review 10.  Medullary thyroid cancer: management guidelines of the American Thyroid Association.

Authors:  Richard T Kloos; Charis Eng; Douglas B Evans; Gary L Francis; Robert F Gagel; Hossein Gharib; Jeffrey F Moley; Furio Pacini; Matthew D Ringel; Martin Schlumberger; Samuel A Wells
Journal:  Thyroid       Date:  2009-06       Impact factor: 6.568
View more
  7 in total

Review 1.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

2.  Pheochromocytoma in Children and Adolescents With Multiple Endocrine Neoplasia Type 2B.

Authors:  Angeliki Makri; Srivandana Akshintala; Claudia Derse-Anthony; Jaydira Del Rivero; Brigitte Widemann; Constantine A Stratakis; John Glod; Maya Lodish
Journal:  J Clin Endocrinol Metab       Date:  2019-01-01       Impact factor: 5.958

Review 3.  MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives.

Authors:  Vincent Amodru; David Taieb; Carole Guerin; Pauline Romanet; Nunzia Paladino; Thierry Brue; Thomas Cuny; Anne Barlier; Frederic Sebag; Frederic Castinetti
Journal:  Endocrine       Date:  2020-05-10       Impact factor: 3.633

4.  Minimally Invasive Surgery (MIS) in Children and Adolescents with Pheochromocytomas and Retroperitoneal Paragangliomas: Experiences in 42 Patients.

Authors:  Martin K Walz; Laura D Iova; Judith Deimel; Hartmut P H Neumann; Birke Bausch; Stefan Zschiedrich; Harald Groeben; Pier F Alesina
Journal:  World J Surg       Date:  2018-04       Impact factor: 3.352

5.  Genetic analysis and clinical investigation of a pedigree with multiple endocrine neoplasia type 2A: A case report.

Authors:  Hong-Jin Zou; Yu-Shu Li; Zhong-Yan Shan
Journal:  Oncol Lett       Date:  2016-08-16       Impact factor: 2.967

Review 6.  Endocrine neoplasms in familial syndromes of hyperparathyroidism.

Authors:  Yulong Li; William F Simonds
Journal:  Endocr Relat Cancer       Date:  2016-05-20       Impact factor: 5.678

Review 7.  A Clinical Roadmap to Investigate the Genetic Basis of Pediatric Pheochromocytoma: Which Genes Should Physicians Think About?

Authors:  Bernardo Dias Pereira; Tiago Nunes da Silva; Ana Teresa Bernardo; Rui César; Henrique Vara Luiz; Karel Pacak; Luísa Mota-Vieira
Journal:  Int J Endocrinol       Date:  2018-03-20       Impact factor: 3.257
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.